Efficacy and safety of vunakizumab versus other interleukin-17A inhibitors in the treatment of moderate-to-severe plaque psoriasis with matching-adjusted indirect comparisons
HE Xiao-ning
GENG Jia-lu
HAN Bing-lin
Abstract：Objective:To compare the efficacy and safety of vunakizumab with other IL-17A inhibitors currently approved for plaque psoriasis in China.Methods:Three IL-17A inhibitors,secukinumab,ixekizumab and xeligekimab,were selected as the reference drugs in this study.A matching-adjusted indirect comparison(MAIC)approach was used to compare the efficacy and safety of vunakizumab with the reference drugs.Results:In terms of efficacy,vunakizumab demonstrated a faster onset of action compared to secukinumab,with significantly higher PASI 75 response rates at week 4 and higher PASI 100 response rates at week 12(34.23%vs 32.90%,P=0.574).However,PASI 75 and PASI 90 response rates at week 12 were lower than those for secukinumab(both P<0.001).Compared to ixekizumab and secukinumab,vunakizumab demonstrated higher PASI 75 and PASI 100 response rates at week 12(88.91%vs 85.80%;33.40%vs 33.00%,85.72%vs 82.10%,P=0.104;36.06%vs 30.20%,P<0.05).In terms of safety,the incidence of adverse events such as upper respiratory tract infections,injection site reactions,and tinea pedis was significantly lower or showed no difference(all P<0.001).Conclusion:Vunakizumab exhibits a faster onset of actin within 4 weeks,achieves a higher PASI 100 response rate at week 12,and higher PASI 75 than that of ixekizumab and xeligekimab,along with a favorable safety profile.
Keywords：matching-adjusted indirect comparisonplaque psoriasisinterleukin-17A inhibitorvunakizumab
Publication Date：2026-02-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：7( 325-331 )